Curis, Inc. · NASDAQ:CRIS

Curis — Technical Presentation (September 2023)

192 slides from Curis's technical presentation, September 2023

  1. Slide 1: This event will be recorded

    1 *This event will be recorded

  2. Slide 2: U2AF1 and SF3B1 mutations induce oncogenic IRAK4 isoforms in MDS and AML

    U2AF1 and SF3B1 mutations induce oncogenic IRAK4 isoforms in MDS and AML Amit Verma, M.B.B.S Professor, Department of Oncology (Medical Oncology), Department of Medicine (Oncology & Hematology), and Department of Developmental & Molecular Biology, Albert Einstein College of Medicine Director, Divisi

  3. Slide 3: TLR/IL1R signaling controls inflammation, apoptosis, differentiation

    TLR/IL1R signaling controls • Inflammation • Apoptosis • Cellular differentiation • IRAK4 family signaling network Rhyasen GW, et al. Br J Cancer. 2015;112(2):232-7. 3

  4. Slide 4: IRAK4: Interleukin Receptor Associated Kinase

    IRAK4: Interleukin 1 Receptor Associated Kinase 4 140 150 IRAK4 - L 1 DD Kinase Domain 460 Protein IRAK4 - S 1 Kinase Domain 360 Smith MA,* Choudhary GS,* et al. Nat Cell Biol. 2019; 21(5):640-650. 4

  5. Slide 5: Exon inclusion is seen in MDS with U2AF1 mutations

    Exon 4 inclusion is seen in MDS with U2AF1 mutations S34F U2AF1 Healthy control Q157P U2AF1 mut R156H U2AF1 mut Q157R U2AF1 mut EXON EXON EXON 3 4 5 MDS, myelodysplastic syndromes. Jackie Boultwood Smith MA,* Choudhary GS,* et al. Nat Cell Biol. 2019; 21(5):640-650. 5 Andrea Pellagatti

  6. Slide 6: IRAK4 exon inclusion in MDS patient bone marrow CD34+ cells

    ( MDS-U2AF1 mu 0.0 (CD34+) IRAK4 exon 4 inclusion in MDS patient bone MDS-U2AF1mut Healthy Control MDS-SFWT marrow CD34+ cells E3 E4 E5 AAG E GT A (Y)n IRA C AG Inclusion TCCTCTCTCTCTATC (Inclusion: U2AF1S34F (312 bp) Healthy Control Healthy Control MDS-SFWTWT MDS-SF MDS-U2AF1mut MDS-U2AF1 mut 1.0 v

  7. Slide 7: IRAK4 exon6 inclusion in MDS patient bone marrow CD34+ cells

    IRAK4 exon6 inclusion in MDS patient bone marrow CD34+ cells Inclusion (280 bp product) 5 6 7 Exclusion (194 bp product) Healthy SF WT MDS U2AF1 SF3B1 Controls E N S E 0 0 0 0 3 6 2 6 9 0 3 :E N S E 0 0 0 0 2 3 9 9 8 1 2 i s o f o r m r a t io 2 .0 L o n g :S h o r t Is o fo r m R a tio * 1 .5 1 .0

  8. Slide 8: SF3B1 mutations associated with retention of IRAK4 exon 6

    MDS/AML samples with SF3B1 mutations are associated with retention of IRAK4 exon 6 in MDS/AML Healthy controls SF3B1 mutants EXON EXON EXON 5 6 7 Jackie Boultwood 8 AML, acute myeloid leukemia; MDS, myelodysplastic syndrome. Andrea Pellagatti

  9. Slide 9: Long IRAK4 isoforms in SF3B1 mutant samples

    Long IRAK4 isoforms in SF3B1 mutant samples Long cDNA encoding full-length IRAK4 protein Atgaacaaacccataacaccatcaacatatgtgcgctgcctcaatgttggactaattaggaagctgtcagattttattgatcctcaagaaggatggaagaagttagctgtagctattaaaaaaccatctggtgatgata gatacaatcagtttcacataaggagatttgaagcattacttcaaactggaaaaagtcccacttctgaatta

  10. Slide 10: IRAK4 isoforms in WT-SF3B1

    IRAK4 isoforms in WT-SF3B1 Sequence 1 Ttgaacaaacccataacaccatcaacatatgtgcgctgcctcaatgttggactaattaggaagctgtca gattttattgatcctcaagaaggatggaagaagttagctgtagctattaaaaaaccatctggtgatgat agatacaatcagtttcacataaggagatttgaagcattacttcaaactggaaaaagtcccacttctgaa ttactgtttgactggggcaccacaaattgcacagttggtgatcttgtggatc

  11. Slide 11: IRAK4 isoforms in WT-SF3B1 undergo ubiquitination

    IRAK4 isoforms in WT-SF3B1 undergo ubiquitination EXON 6 140 150 188 217 IRAK4 - L 1 DD Kinase Domain 460 Protein Sequence 1 1 DD 1 Stop codon 191 Sequence 2 1 Kinase Domain 243 IRAK4-S2 IRAK4-S1 IRAK4-S1 IRAK4-S2 Figure 2 IRAK4-L IRAK4-L Vector MG132 (10µM) Flag IRAK4 β-actin HEK-293T 11

  12. Slide 12: IRAK4 isoforms in WT-SF3B1

    IRAK4 isoforms in WT-SF3B1 EXON 6 140 150 188 217 IRAK4 - L 1 DD Kinase Domain 460 Protein Sequence 1 1 DD 1 Stop codon 191 Sequence 2 1 Kinase Domain 243 12

  13. Slide 13: IRAK4 knockdown causes increased myeloid differentiation

    IRAK4 knockdown causes increased myeloid differentiation STEP 1 STEP 4 Prepare cells according to STEP 2 STEP 3 Count colonies and your institution’s protocols. Add cells to Plate and incubate 10- analyze samples on Adjust cell concentration in MethoCultTM 14 days flow cytometry Iscove’s MDM + 2% FB

  14. Slide 14: CA-4948 IRAK4 kinase inhibitor blocks the TLR signaling pathway

    CA-4948 IRAK4 kinase inhibitor blocks the toll-like receptor (TLR) signaling pathway Curis 14 Bob Booher

  15. Slide 15: Targeting IRAK4 with CA-4948

    Targeting IRAK4 with CA-4948 In vitro culture DMSO or CA-4948 Differentiation (125 nM) Vehicle or CA-4948 Engraftment / (12.5 mg/kg) Differentiation Xenograft Primary MDS/AML patient-derived BM cells (SF3B1 mutants) AML, acute myeloid leukemia; DMSO, dimethyl sulfoxide; MDS, myelodysplastic syndrome

  16. Slide 16: IRAK4 inhibitor increases myeloid differentiation from SF3B1 mutant samples

    IRAK4 inhibitor increases myeloid differentiation from SF3B1 mutant primary MDS/AML samples AML, acute myeloid leukemia; MDS, myelodysplastic syndrome. 16

  17. Slide 17: IRAK4 inhibitor decreases leukemic engraftment in PDX models

    IRAK4 inhibitor causes decreased leukemic engraftment in vivo in PDX models SAC and Primary Vehicle or Primary Isolate Secondary MDS/AML CA-4948 engraftment Human Bone engraftment BM cells (12.5 mg/kg) marrow and Xenograft spleen cells Xenograft AML, acute myeloid leukemia; BM, bone marrow; MDS, mye

  18. Slide 18: Emerging pathogenic role of innate immune signaling in MDS/AML

    Emerging pathogenic role of innate immune signaling in MDS/AML AML, acute myeloid leukemia; MDS, myelodysplastic syndrome. 18

  19. Slide 19: Acknowledgements

    Acknowledgements • Gaurav Choudhary Cincinnati Children’s Hospital Medical Center • Srinivas Aluri • Daniel T. Starczynowski • Tushar D. Bhagat • Molly A. Smith • Leya Schwartz • Kith Pradhan Stem Cell Studies (Einstein) • Aditi Shastri • Uli Steidl • Shanisha Gordon-Mitchell • Britta Will • Sanchar

  20. Slide 20: Questions?

    IRAK4 | Symposium Questions? fon CUS’

  21. Slide 21: Incorporating IRAK inhibition in the treatment of MDS

    Incorporating IRAK inhibition in the treatment of MDS Guillermo Garcia-Manero, M.D. Symposium Co-Chair Chief Professor, Department of Leukemia; Chief, Section of Myelodysplastic Syndromes and Deputy Chair, Translational Research, Department of Leukemia, Division of Cancer Medicine, The University of

  22. Slide 22: Agenda

    Agenda • Discuss basic concepts of MDS • Review clinical activity of CA4849 in RR MDS • Discuss potential role of IRAK inhibitor in MDS 22

  23. Slide 23: Diagnosis of MDS is based on morphology

    Diagnosis of MDS is based on morphology Courtesy of Dr. Carlos Bueso-Ramos 23

  24. Slide 24: Cytogenetic Scoring System in MDS

    Cytogenetic Scoring System in MDS (Schanz et al., JCO, 2011) 24

  25. Slide 25: Genomics of MDS

    Genomics of MDS Papaemmanuil et al Blood 2013;122:3616-27 25

  26. Slide 26: Proposed treatment algorithm for patients with MDS 2023

    Proposed treatment algorithm for patients with MDS 2023 MDS LOWER RISK HIGHER RISK (IPSS low, INT-1) (IPSS INT-2, high) (IPSS-R VL, L, INT) (IPSS-R INT, H, VH) (BM blasts < 10%) (BM blasts > 10%) IPSS-M Any age Age <70-75 Age >70-75 Iron chelation Intensive chemotherapy HMA Growth factors HMA Clinic

  27. Slide 27: SOC: Azacitidine survival

    SOC: Azacitidine Log-Rank p=0.0001 1.0 HR = 0.58 [95% CI: 0.43, 0.77] 0.9 Deaths: AZA = 82, CCR = 113 Proportion Surviving 0.8 Difference: 9.4 months 0.7 0.6 50.8% 0.5 24.4 months 0.4 15 months 26.2% 0.3 AZA 0.2 CCR 0.1 0.0 0 5 10 15 20 25 30 35 40 Time (months) from Randomization Fenaux et al. Lanc

  28. Slide 28: Doublets in Higher Risk MDS

    Doublets in Higher Risk MDS • Panther (P-3001): azacytidine +/- pevonedistat • Azacytidine + APR-246 for p53 mutated MDS • HMA+ anti CD47 • HMA + venetoclax • HMA + sabatolimab 28

  29. Slide 29: Phase 1 study of azacitidine combined with venetoclax for MDS

    A phase 1 study of azacitidine combined with venetoclax for myelodysplastic syndrome and chronic myelomonocytic leukemia Alexandre Bazinet, MD, MSc, FRCPC Leukemia Fellow Updated EHA 22 P757 Lancet Hematology 2022 Department of Leukemia University of Texas MD Anderson Cancer Center 29

  30. Slide 30: Responses (N = 23 ITT analysis)

    Responses (N = 23 ITT analysis) Response All HMA-naïve HMA-failure (Modified IWG) (n = 23) (n = 17) (n = 6) n (%) or n (%) or n (%) or median [range] median [range] median [range] ORR 20 (87) 14 (82) 6 (100) CR 3 (13) 3 (18) 0 (0) mCR 17 (74) 11 (65) 6 (100) mCR + HI 5 (22) 5 (29) 0 (0) mCR alone 12

  31. Slide 31: Overall survival (N = 23)

    Overall survival (N = 23) Median follow-up: 13.2 months 31

  32. Slide 32: Phase 3 VERONA Study Design and Endpoint

    Phase 3 VERONA (NCT04401748) Study Design and Endpoint VERONA Study Design Randomized 1:1 Venetoclax (PO QD D1-14) Phase 3 + Azacitidine (IV/SC QD D1-7*) Newly Diagnosed Higher-Risk MDS (N=500) Placebo (PO QD D1-14) + Azacitidine (IV/SC QD D1-7*) *7 days within the first 9 calendar days/28 day cycle

  33. Slide 33: Targeted Options in MDS

    Targeted Options in MDS • IDH-2 (5-10%): enasidenib, venetoclax • IDH-1 (5%): ivosidenib, venetoclax • Flt-3 (15%): multiple agents • TP53 (10%): anti-CD47 ? • NPM1 (1%): ara-C based • Splicing: IRAK4, H3BIO, Clk 33

  34. Slide 34: Enasidenib in MDS: Response Rates

    Enasidenib in MDS: Response Rates Arm A Arm B (HMA- Response (Untreated) failure) Evaluable AZA + ENA ENA (N = 46) (N = 25) (N = 21) Overall response rate (ORR), n (%) 30 (68) 21 (84) 9 (43) Complete remission (CR) 11 (24) 6 (24) 5 (24) Partial remission (PR) 3 (7) 2 (8) 1 (5) Marrow CR (mCR) 12 (26

  35. Slide 35: TakeAim Leukemia Phase 1/2a study of emavusertib

    TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS Guillermo Garcia-Manero, MD1, Eric S. Winer, MD2, Daniel J. DeAngelo, MD, PhD2, Stefano Tarantolo, MD3, David A. Sallman

  36. Slide 36: Emavusertib, An Oral IRAK4 Inhibitor

    Emavusertib, An Oral IRAK4 Inhibitor IRAK4/Emavusertib Co-crystal Structure • Emavusertib: • Selective, small molecule inhibitor of IRAK4 • ATP-competitive, type 1 inhibitor, reversible • Excellent drug-like properties: • Orally bioavailable (>100% dog/mouse) • Moderate plasma binding (77% human) •

  37. Slide 37: Emavusertib: Study Design

    Emavusertib: Study Design TakeAim Leukemia (NCT #04278768): Open-label, single arm, Phase 1/2 dose escalation and expansion 3+3 study design in R/R AML or high-risk MDS (HR-MDS) Study Objectives Dose Escalation: Dose Expansion: 1ᵒ: Determine maximum tolerated dose 200/300/400/500 mg BID 300 mg BID D

  38. Slide 38: Emavusertib: Single-Agent Activity in R/R HR-MDS with Spliceosome Mutation

    Emavusertib: Single-Agent Activity in R/R HR-MDS with Spliceosome Mutation Duration on Blasts # of Prior Blasts Dose (BID) IPSS-R Baseline Molecular Mutations emavuserti Best % Change Therapies Baseline b (mos) Response Very High U2AF1 ,ASXL1, NF1, PHF6, -82% 200 mg 1 5.7 11 2 Risk GFI1, KDM6A, TET2

  39. Slide 39: ONTIME Trial: Median Overall Survival in HMA Failure

    ONTIME Trial: Median Overall Survival for Pts with Primary HMA Failure - Blinded, Centralized Assessment Garcia-Manero. Lancet Oncology 2016 39

  40. Slide 40: Innate Immune Signal Deregulation and KDM6B Drive MDS/CMML

    Innate Immune Signal Deregulation including Overexpression of KDM6B Drives Pathogenesis of MDS/ CMML Vav-KDM6B mice r e la tiv e h K D M 6 B R N A le v e l K D M 6 B e x p re s s io n in M D S 30 ( f o ld to n o r m a l c o n tr o l) 25 s u rv iv a l W BC 20 WT V a v -K D M 6 B 12 P<0.05 P e r c e n

  41. Slide 41: Vav-KDM6B-Tg mice display MDS-like phenotype

    Vav-KDM6B(JMJD3)-Tg mice display MDS-like phenotype , particularly after exposure to chronic innate immune stimulation LPS injection post-treat WT OR VAV-KDM6B (6mg/mouse, 6wk) hematological analysis #PB: significantly lowered white #BM: significantly lowered BM #HSC function: significantly reduced

  42. Slide 42: Potential role of IRAK inhibition in MDS

    Potential role of IRAK inhibition in MDS • Examples HR MDS front line • Doublet HMA+ CA4948 • Triplet HMA+venetoclax+ CA4948 • Monotherapy in HMA failure HR MDS • Consider potential role in lower risk MDS 42

  43. Slide 43: Thank you

    Thank you • Guillermo Garcia-Manero • Section of MDS • Department of Leukemia • MD Anderson Cancer Center • ggarciam@mdanderson.org 43

  44. Slide 44: Questions?

    IRAK4 | Symposium Questions? fon CUS’

  45. Slide 45: Therapeutic Potential of CLK/DYRK Kinase Inhibition in Myeloid Malignancies

    Therapeutic Potential of CLK/DYRK Kinase Inhibition in Myeloid Malignancies Omar Abdel-Wahab, M.D. Edward P. Evans Chair in MDS, Director, Memorial Sloan Kettering Cancer Center (MSK) for Hematologic Malignancies; Member, Human Oncology and Pathogenesis Program & Leukemia Service 45

  46. Slide 46: Disclosures

    Disclosures Consulting: Speaking fee: Research support • Incyte Corporation • Daiichi Sankyo Europe GmbH • LoxoOncology/Eli Lilly • AstraZeneca Pharmaceuticals LP • Curis • Pfizer Inc. • Merck Sharp & Dohme Corporation • Nurix Therapeutics • Janssen Global Services, LLC Scientific advisory board • M

  47. Slide 47: CA-4948's kinase targets

    CA-4948’s kinase targets CA-4989 Binding Affinity Activity (DiscoverX) Kinase Kd (nM) FLT3-variant Kd (nM) IRAK4 23* FLT3 31 IRAK1 12,000 FLT3 (D835H) 4.6 IRAK2 >20,000 FLT3 (D835V) 44 IRAK3 8,500 FLT3 (D835Y) 2.5 FLT3 (ITD) 7.8 FLT3 (ITD, D835V) 31 FLT3 (ITD, F691L) 20 Kinase Kd (nM) FLT3 (K663Q) 4

  48. Slide 48: CLK & DYRK kinase families

    CLK & DYRK kinase families Family of highly-related dual specificity kinases: phosphorylate Tyrosine & Serine/Threonine residues NLSDH Y NLS PEST His S/T DYRK1A N Kinase C 763 aa NLSDH Y PEST DYRK1B N Kinase C 629 aa NLSDH Y DYRK2 N Kinase C 601 aa NAPA DH Y DYRK3 N Kinase C 588 aa NAPA NLS DH Y DYR

  49. Slide 49: Genome-wide CRISPR screens identify drug-gene interactions in AML

    Genome-wide CRISPR screens identify drug-gene interactions in AML 49

  50. Slide 50: Genome-wide CRISPR screens identify drug-gene interactions in AML

    Genome-wide CRISPR screens identify drug-gene interactions in AML Resistance Sensitizer 50

  51. Slide 51: Genome-wide CRISPR screens identify drug-gene interactions in AML

    Genome-wide CRISPR screens identify drug-gene interactions in AML Resistance Venetoclax sensitizing pathways Sensitizer 51

  52. Slide 52: Genome-wide CRISPR screens identify drug-gene interactions in AML

    Genome-wide CRISPR screens identify drug-gene interactions in AML Resistance Sensitizer 52

  53. Slide 53: Genome-wide CRISPR screens identify drug-gene interactions in AML

    Genome-wide CRISPR screens identify drug-gene interactions in AML Resistance RNA processing/splicing factors Sensitizer 53

  54. Slide 54: Focused CRISPR screens to identify drug-gene interactions

    Focused CRISPR screens to identify drug- gene interactions Focused CRISPR library Targeting 490 RBPs with 2,900 sgRNAs (~6-8 sgRNA/gene) MOLM13 Cas9 expressing AML cell line (MLL-AF9 FLT3ITD) RBD, RNA-binding domains; RBP, RNA-binding protein; sgRNA, single-guide RNA. Wang EW, et al. Cancer Cell. 20

  55. Slide 55: Focused CRISPR screens to identify drug-gene interactions

    Focused CRISPR screens to identify drug-gene interactions Resistance Synergy 55

  56. Slide 56: Focused CRISPR screens to identify drug-gene interactions

    Splicing-dependent kinases: • Spliceosome assembly • SR protein shuttling • mRNA splicing Focused CRISPR screens to identify drug-gene interactions Resistance Synergy 56

  57. Slide 57: Targeting splicing-dependent kinases synergizes with venetoclax

    Targeting splicing-dependent kinases synergizes with venetoclax SM09419 Pan-CLK/DYRK inhibitor 57

  58. Slide 58: SM09419 induces intron retention of RNA splicing factors

    SM09419 induces intron retention of RNA splicing factors NMD, nonsense-mediated decay 58

  59. Slide 59: SM09419 induces intron retention of RNA splicing factors

    SM09419 induces intron retention of RNA splicing factors DMSO, dimethyl sulfoxide. 59

  60. Slide 60: SM09419 induces FLT3 poison exon inclusion

    SM09419 induces FLT3 poison exon inclusion & FLT3 downregulation “Poison exon” DMSO, dimethyl sulfoxide; TPM, transcripts per million. 60

  61. Slide 61: SM09419 overcomes venetoclax resistance in AML cells

    SM09419 overcomes venetoclax resistance in AML cells Venetoclax resistant IC50, half-maximal inhibitory concentration. 61

  62. Slide 62: Impact of CLK/DYRK inhibition on apoptosis regulators & FLT3

    Impact of CLK/DYRK inhibition on apoptosis regulators & FLT3 IC50, half-maximal inhibitory concentration. 62

  63. Slide 63: SM09419 overcomes venetoclax resistance in PDX models

    SM09419 overcomes venetoclax resistance in PDX models Patient Prior therapies Response Start of venetoclax End of venetoclax Sample date Genetic alterations Primary 1 VEN+Azacytidine 01/18/2019 02/27/2019 06/05/2020 RUNX1, PTPN11, FLT3, SF3B1, STAG2 refractory VEN+Low-dose Primary 2 01/03/2017 04/06

  64. Slide 64: Conclusions

    CLK/DYRK inhibition may broaden CLK/DYRK inhibition results in the patient population considered genome-wide alterations in for to be responsive to CA-4948 splicing and affects expression (patients with broader range of of a number of apoptotic splicing factor mutations and FLT3 regulators and FLT3

  65. Slide 65: Questions?

    IRAK4 | Symposium Questions? fon CUS’

  66. Slide 66: Emavusertib for Acute Myeloid Leukemia

    Emavusertib for Acute Myeloid Leukemia Eric S. Winer, M.D. Symposium Co-Chair Clinical Director, Adult Leukemia Institute Physician, Dana-Farber Cancer Institute Assistant Professor of Medicine, Harvard Medical School 66

  67. Slide 67: The State of Acute Myeloid Leukemia

    The State of Acute Myeloid Leukemia Median Age at Diagnosis • Accounts for only 1.2% of all cancer deaths 68 - Estimated new cases 2022: 20,050 - Estimated Deaths 2022: 11,540 - 5-year relative survival (2018): 28.3% Percent surviving 5 years • Median age is 68 years of age • Risk Factors: 28.3% - A

  68. Slide 68: The State of AML – novel approved therapies

    The State of AML – novel approved therapies We Are Doing Great Work! Age 15-59 • Midostaurin months, Placebo 25.6 months • Vyxeos (CPX-351) • Venetoclax • Glasdegib • Gilteritinib • Ivosidenib (with aza) Age >60 • Quizartinib (induction) Burnett A et al. J Clin Oncol 29:487-494 68

  69. Slide 69: The State of AML – novel approved therapies

    The State of AML – novel approved therapies Are we doing great work…..? Age 15-59 • Midostaurin (induction) - Midostaurin 74.7 months, Placebo 25.6 months • Vyxeos (CPX-351) (induction) - Vyxeos 9.6 months, 7+3 5.95 months • Venetoclax (with Aza) - Aza/Ven 14.7 months, Aza alone 9.6 months • Glasdeg

  70. Slide 70: IRAK-4 Pathway – Enter the Myddosome

    IRAK-4 Pathway – Enter the Myddosome Balka KR and DeNardo D. J Leukoc Biol. 2019;105:339–351; 70

  71. Slide 71: CA-4948: Emavusertib – an IRAK4/FLT3 kinase inhibitor

    CA-4948: Emavusertib – an IRAK4/FLT3 kinase inhibitor Emavusertib with interaction points on IRAK4 • Potent inhibition of IRAK4 with significant inhibition • Demonstrates activity in other kinases such as CLK1, of pIRAK1 in PK-PD studies CLK2, CLK4, FLT3, DYRK1A, DYRK1B, TrkA, TrkB, Haspin, and NEK1

  72. Slide 72: Emavusertib – Kinome map

    Emavusertib – Kinome map Emavusertib Staudt et al, Int J. Mol Sci 2018 19(10):3198; 72

  73. Slide 73: IRAK kinases are an early activator in AML transition

    IRAK kinases are an early activator in AML transition • Generated induced pluripotent stem cells (iPSC) through CRISPR-Cas9 to sequentially introduce ASXL1, SRSF2, NRAS and FLT3. • Evaluated changes of transcriptomes and chromatin at each stage to identify dysregulation of inflammatory signaling in

  74. Slide 74: IRAK4: The long and the short

    IRAK4: The long and the short • Evaluation of gene regulation at the isoform level in MDS and AML • Discovered that IRAK4 was the most significantly altered by encoding a Long protein (IRAK4-L) what associated with MyD88 and activated NF-κB and MAP-kinase - Knockdown IRAK4L resulted in suppression o

  75. Slide 75: IRAK4: The long and the short

    IRAK4: The long and the short Guillamot and Aifantis, Nat Cell Bilo 2019;20(5):536-537 75

  76. Slide 76: Overcoming AML and chemotherapy resistance

    Overcoming AML and chemotherapy resistance • Emerging data describing IRAK signaling pathway as a breakthrough mechanism of adaptive resistance to chemotherapy - Includes daunorubicin and patients with RAS mutations • In studies evaluating adaptive resistance mechanism after FLT3i treatment: - Activ

  77. Slide 77: Emavusertib – Clinical data

    Emavusertib – Clinical data • 90 total patients treated (58 AML, 32 HR-MDS) 8 AML Patients 7 AML Patients 84 AML Patients Spliceosome Mutation** with FLT3 Mutation** • Toxicities included infections, all comers, all dose levels* anemia, and elevated CK 100% 0% 0% 80% • RP2D is 300mg BID, with -20% -

  78. Slide 78: Patient Response

    Patient Response Cycle Morphology Mutations FLT3 60% cellular Screen BCOR, U2AF1 (15.6% VAF) WT1 ITD AR 0.1 30% Blasts 10% cellular ITD AR <0.05 C2D1 N/A <5% blasts (suspicious) 10-40% cellular C4D1 BCOR, U2AF1 (1.3% VAF) WT1 FLT3-ITD negative <5% blasts 20% cellular C7D6 BCOR, NRAS, U2AF1 (4.3% VAF

  79. Slide 79: Next steps: rationale for combination

    Next steps: rationale for combination • Previously shown pre-clinical data with gilteritinib Combination with Aza/Ven and quizartinib • Data in MDS evaluating IRAK1/4 inhibitor with ABT-263 (Navitoclax) showed potent synergy in MDS/AML cells and 100% in mouse models. Relative Cell Growth p<0.05 50%

  80. Slide 80: IRAK4 in AML: rationale and conclusions

    IRAK4 in AML: rationale and conclusions IRAK4 is an important kinase and mediator of Early phase in AML and MDS with CA-4948 AML leukemogenesis have demonstrated efficacy as a single agent AML has a significant increase in the IRAK4-L Data demonstrates impressive synergy between which provides an ex

  81. Slide 81: Questions?

    IRAK4 | Symposium Questions? fon CUS’

  82. Slide 82: IRAK4 as a therapeutic target in GI cancers

    IRAK4 as a therapeutic target in GI cancers Kian-Huat Lim, M.D., Ph.D. Associate Professor, Division of Oncology, Department of Medicine, Washington University School of Medicine in St. Louis 82

  83. Slide 83: Disclaimer

    Disclaimer Clinical trials: Merck, BMS, Verastem, Takeda, Biomed Valley, Ipsen, Celgene, AstraZeneca, CURIS, PanCan. Advisory: Jacobio, Genentech 83

  84. Slide 84: Outline

    Outline Introduction Role of IRAK4 in GI cancers • Pancreatic ductal adenocarcinoma (PDAC) • Colorectal cancer (CRC) • Biliary tract • Gastric cancer Role of IRAK4 in anti-tumor T cell response 84

  85. Slide 85: The incidence of and death due GI cancers is rising

    The incidence of and death due GI cancers is rising Incidence Death GI, gastrointestinal. 85

  86. Slide 86: PDAC: We still use chemotherapy for all patients

    PDAC: We still use chemotherapy for all patients N Engl J Med 2013; 369:1691-1703 Combination chemotherapies are not curative and have significant side effects PDAC, primary ductal adenocarcinoma; FOLFIRINOX, folinic acid, fluorouracil, irinotecan, and oxaliplatin. 1. Conroy T, et al. N Engl J Med.

  87. Slide 87: PDAC cells are driven by oncogenes and shielded by fibrotic stroma

    PDAC cells are driven by powerful oncogenes and shielded by a fibrotic stroma CCR2, CXCR2, CCR5, CSF1R Trichrome Anti-PD1, anti-CTLA4 Agonistic anti-CD40 CK19/CD8/DAPI PDAC, primary ductal adenocarcinoma. 87

  88. Slide 88: The NF-κB pathway is a therapeutic target in PDAC

    The NF-κB pathway is a therapeutic target in PDAC The innate inflammation pathway • RELA, the p65 subunit of NF-kB, was constitutively nuclear (activated) in 67% of PDAC and associated with poor prognosis • Associated with treatment resistance, invasion, metastasis and immune evasion • Targeted dele

  89. Slide 89: Activated IRAK4 correlates with phospho-RELA and poor prognosis in PDAC

    Activated IRAK4 positively correlates with phospho-RELA/NF-κB1 and poor prognosis in PDAC PDAC, primary ductal adenocarcinoma. Zhang D, et al. Clin Cancer Res. 2017;23(7):1748-1759. 89

  90. Slide 90: IRAK4 kinase activity is required to activate RELA and NF-κB in PDAC

    IRAK4 kinase activity is required to activate RELA and NF-κB pathway in PDAC PDAC, primary ductal adenocarcinoma. Zhang D, et al. Clin Cancer Res. 2017;23(7):1748-1759. 90

  91. Slide 91: IRAK4 controls multiple pathogenic processes in PDAC

    IRAK4 controls multiple pathogenic processes in PDAC TCGA PDAC (Generated in GEPIA 2) Pearson r = 0.3 ● ● 4 ● p= 4.1e−05 ● ● ● ● Differential gene expression by ● HAS2 TPM (log2) ● ● ● ● ● ● ● IRAK4 in KP2 (FDR<0.1) 3 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● Contro

  92. Slide 92: High intratumoral hyaluronan is a therapeutic target in PDAC

    High intratumoral hyaluronan is a therapeutic target in PDAC HAS1 HAS2 HAS3 KP2 4 **** **** **** 3 **** Relative mRNA level * ns 2 ns ns ns ns ns ns 1 0 vector: + + + sgIRA K 4#: 1 21 2 1 21 2 1 21 2 m IRA K 4: ++ ++ ++ Pasi A, et al. FEBS J. 2019;286(15):2937-2949. AGGTATTCCC GGTCAGCCCC GGGAAATCCA

  93. Slide 93: CA-4948 and Gemcitabine/Paclitaxel in preclinical KPC model

    Combination of CA-4948 and Gemcitabine/Paclitaxel in preclinical KPC model KPC (p48-Cre/p53flox/flox/LSL-KRASG12D) mice CA-4948 (from CURIS) Median Cleaved caspase-3 Pan-CK DAPI Treatment n survival(d) Vehicle Gem/pacli 300 **** • 1st and only in-class IRAK4 inhibitor 100 Vehicle 13 20 250 200 * CC3

  94. Slide 94: ETCTN P10522: Phase 1 trial of CA-4948 with gemcitabine and nab-paclitaxel

    ETCTN P10522: A Phase 1 Clinical Trial of CA-4948 in Combination with Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma Status: actively accruing WU, U Chicago, NYU, Yale, Columbia, UC Irvie, U Pittsburg, U Kentucky, U Oklahoma, Ohio State PI: Patrick Grierson,

  95. Slide 95: Immunotherapies struggle to succeed in clinical trials for PDAC

    Immunotherapies struggle to succeed in clinical trials for PDAC Updates 2023 sotiga/nivo/chemo inferior to nivo/chemo CCR2/5i/nivo/chemo completed at Wash U: some SD CSF1R + anti-PDL1: 0% ORR RCT on hyaluronidase negative FAKi study at Wash U: some SD PDAC, pancreatic ductal adenocarcinoma; RCT, ran

  96. Slide 96: T cells inside PDAC bear activation and exhaustion signatures

    T cells inside PDAC bear both activation AND exhaustion signatures PDAC (TCGA, PanCancer Atlas, N=180) USA today CXCL9 T cell signature (Spranger et al.) CXCL10 CCL3 Pearson r = 0.8943, P < 0.0001 T cell exhausted (Tisorh et al.) CCL4 50 HLA-DMB HLA-DOA CD8A GZMK 40 ICOS HLA-DOB IRF1 CCL2 30 CCL4 Cy

  97. Slide 97: IRAK4 controls suppressive chemokines and checkpoint ligands

    IRAK4 controls several suppressive chemokines and checkpoint ligands KP2 cells (from a KPC mouse) Downregulated in IRAK4 KO cells, all FDR<0.05 Independently confirmed by IRAK4 rescue and IRAK4 inhibitor Gene log2FC adj.P.Val Reported function in PDAC CCL2 -0.5411205 1.12E-03 Recruits monocytes, gra

  98. Slide 98: Conditional IRAK4flox/flox KPC mice

    Conditional IRAK4flox/flox KPC p48-Cre/p53f/f/LSL-KRASG12D (KPC) 4 weeks 5 weeks 6 weeks End-stage LoxP Exons LoxP FRT GFP WT KPC 1 2 3 4 5 6 7 8 91011 12 CAG promoter Cre recombinase GFP G F P e xp re ssio n 1 CAG promoter WT IRAK4f/f IRAK4f/f KPC IRAK4 IHC 120 100 p48-Cre/IRAK4f/f and global IRAK4

  99. Slide 99: Conditional IRAK4 KPC mice have lower TAMs and CAFs and more T cells

    scRNAseq: whole PDAC tumor flox/flox Conditional IRAK4 KPC mice have lower intratumoral TAMs and CAFs and more T cells myCAF/iCAFs myCAF/iCAFs M2 TAM M2 TAM Monocytes Monocytes M1 TAM TNK TNK M1 TAM Endothelial cells Endothelial cells Tumor Tumor cells cells CAF, cancer-associated fibroblast; TAM, t

  100. Slide 100: Conditional IRAK4 KPC mice have higher activated T cells

    Conditional IRAK4flox/flox KPC mice have higher intratumoral and systemic activated T cells I CD4 CD45 DAPI CD8 CD45 DAPI 8 J CD4 Ki-67 DAPI CD8 Ki-67 DAPI 0.8 **** 15 0.15 **** ** ** % Ki-67+ CD8+ area % Ki-67+ CD4+ area 6 WT 0.6 % CD4+ area % CD8+ area WT 10 0.10 4 0.4 5 0.05 2 0.2 IRAK4f/f IRAK4f

  101. Slide 101: Conditional IRAK4 KPC mice respond to checkpoint immunotherapy

    Conditional IRAK4flox/flox KPC mice respond to checkpoint immunotherapy Immunotx.5 doses WT N Median OS (d) Vehicle 20 20.5 ns 100 Immunotx. 12 17.5 ns IRAK4f/f **** Percent survival 80 Vehicle 16 20 Immunotx. 11 47 **** 60 Immunotherapy: anti-CTLA4 + anti-PD1 twice weekly 40 20 0 0 20 40 60 80120 D

  102. Slide 102: CA-4948 plus immunotherapy is an effective combination

    CA-4948 plus immunotherapy is an effective combination Autochtonous KPC pharmacologic treatment % survival 100 Treatment N Median OS at 60d Vehicle 13 20 0 * 0 CA-4948 9 28 Percent survival 80 Gem/Pacli (chemo) 8 25 *** 0 CA-4948+chemo 9 41.5 0 60 Gem+immunotx. 12 17 0 CA-4948+Gem *** * 22 51 42 +Im

  103. Slide 103: Combo-treated PDAC showed extensive necrosis and lymphoid aggregates

    Combo-treated PDAC showed extensive necrosis and lymphoid aggregates in revision PDAC, pancreatic ductal adenocarcinoma. 103

  104. Slide 104: Single patient compassionate use

    Single patient compassionate use 104

  105. Slide 105: Activated IRAK4 correlates with phospho-RELA in colon cancer

    Activated IRAK4 positively correlates with phospho-RELA and poor prognosis in colon cancer Pooled TMAs (US Biomax) p-IRAK4 (T345) IHC scored by scanner Pooled TMAs Normal(US Biomax) colon p-IRAK4 Normal (T345) IHC scored adjacent by scanner Ulcerative colitis Normal colon Normal adjacent Ulcerative

  106. Slide 106: IRAK4 promotes NF-κB at baseline and upon chemotherapy

    IRAK4 promotes NF-κB at baseline and upon chemotherapy exposure Chemo: Normal Colon cancer DLD-1 KM12 FOLFOX o 2 8C 2 16 0 0 -L1 -L C D-1 -29 O co- 12 Vo D-1 T 1 48 62 20 620 shIRAK4: S #1 #2 S #1 #2 FH CC HT RK Ca KM Lo DL HC SW SW SW6 SW p-IRAK1 100kDa Total IRAK4 48kDa (short exposure ) 100kDa p-

  107. Slide 107: IRAK4i potentiates chemotherapy

    IRAK4i potentiates chemotherapy Li et al. JCI Insight. 2019 Oct 3;4(19):e130867 J Clin Invest. 2020 Sep 1;130(9):4771-4790 107

  108. Slide 108: NCI ETCTN 10655: CA-4948 with FOLFOX + Bevacizumab in colorectal cancer

    NCI ETCTN 10655: Phase 1 Clinical Trial of CA-4948 in Combination with FOLFOX + Bevacizumab as Frontline Treatment in Patients with Metastatic Colorectal Cancer PI: Susanna Ulahannan, M.D., Stephenson Cancer Center at Oklahoma University CrD Mentor: Thomas George, M.D., University of Florida in Gain

  109. Slide 109: IRAK4 is a novel therapeutic target in GI cancers

    IRAK4 is a novel therapeutic target in GI cancers • Tumor intrinsic IRAK4 activation drives MAPK and NF-kB activity→ treatment resistance • Tumor and stromal IRAK4 activation drives collagen and hyaluronan deposition • Tumor IRAK4 activation drives secretion of suppressive chemokines and checkpoint

  110. Slide 110: Thanks for your attention!

    Thanks for your attention! Acknowledgements Wash U School of Medicine in St. Louis Lim Lab • Ashenafi Bulle • Frank Liu • Sapana Bansod • Lin Li • Timothy Chen • Vikas Somani • Patrick Grierson • Justin Xu • Ali Khawar • Yutong Geng Past members: Qiong Li (Assist. Prof, Renji), Qing Wei (Renji), Paa

  111. Slide 111: Questions?

    IRAK4 | Symposium Questions? fon CUS’

  112. Slide 112: Treatment of Melanoma Brain Metastases with Combined IRAK4 and PD-1 Inhibition

    Treatment of Melanoma Brain Metastases with Combined IRAK4 and PD-1 Inhibition Bently Doonan, M.D., M.S. Assistant Professor, Division of Hematology & Oncology, University of Florida College of Medicine 112

  113. Slide 113: Melanoma Brain Metastases (MBM)

    Melanoma Brain Metastases (MBM) • Melanoma will be the 2nd most common malignancy by 20401 • 75% of patients will have MBM at their time of death2 • Current landscape of treatment favors combination CTLA-4/PD-1 therapy or targeted therapy if BRAF mutated3 - Combo ICI 55% intracranial response - BRAF

  114. Slide 114: Inflammation as driver of suppressive TME

    Inflammation as driver of suppressive TME A B C D E Inflammation as a key driver of suppressive TME of MBM A. MBM express high levels of pro-inflammatory cytokines and chemokines, converting their anti-tumor effect into pro-growth signals through the TRL:IL-1R/MyD88/IRAK-4 axis B. Tumors are compris

  115. Slide 115: IRAK4 in Melanoma

    IRAK4 in Melanoma • Upregulation of IRAK-4 in tumors leads to constitutive activation of NF-κB, JNK, and MAPK1,2 • Previous work has shown upregulation of IRAK-4 in cutaneous melanoma, which promotes carcinogenesis regardless of direct mutation or not3 • IRAK-4 upregulation is associated with increa

  116. Slide 116: IRAK4 expression in MBM

    IRAK4 expression in MBM IHC analysis of human MBM samples (IRAK4, IRAK1, NFKB) A B C MERGE (60x) pIRAK-4 CD45 GFAP DAPI MERGE (60x) pIRAK-1 CD45 GFAP DAPI MERGE (60x) pNF-κB CD45 GFAP DAPI MM3088 MM3712 MM3042 IHC, immunohistochemistry; MBM, melanoma brain metastases. Von Roemeling CA, et al. Clin C

  117. Slide 117: NF-κB pathway protein expression in MBM

    NF-κB pathway protein expression in MBM 80 Relative Protein Expression normal cortex Met. Melanoma 60 40 20 0 IκBε IκBα p53 IL-1 RI c-Rel BCL10 IRAK1 IRF5 IRF8 JNK2 TLR2 ASC CARD6 JNK1/2 MYD88 NFκB1 NFκB2 RelA/p65 SOCS6 STAT2 TRAF2 IL-17 RA IL-18 Rα p53 (pS46) STAT1p91 IKK2/IKKβ SHARPIN cIAP1/BIRC2

  118. Slide 118: CA-4948 decreases NF-κB, MAPK, and pERK in model of MBM

    CA-4948 decreases NF-κB, MAPK, and pERK in model of MBM merge pNF-κB P65S536 CD45 GFAP DAPI merge pERKT202/Y204 CD45 GFAP DAPI 0.0376 B16 % pNF-κB P65S536+ 25 vehicle 20 vehicle 15 10 5 CA-4948 0 le 48 e hic -49 V CA CA-4948 merge pP38T180/Y182 CD45 GFAP DAPI B16 % pP38T180/Y182+ 80 0.0005 vehicle 6

  119. Slide 119: CA-4948 does not inhibit antigen processing or T cell activation

    CA-4948 does not inhibit antigen processing, presentation or T cell activation (+ ctrl) 3000 IFNγ (pg/mL) n.s. 2000 Effects of CA-4948 does not inhibit antigen processing, presentation, or T cell activation. Mouse dendritic cells harvested from splenic isolation and either cultured alone or subjecte

  120. Slide 120: Emavusertib reduces TAM infiltration and PD-L1 expression in MBM

    Emavusertib reduces TAM infiltration and PD-L1 expression in MBM merge GFAP F4/80 PD-L1 DAPI vehicle combination Analysis of preclinical MBM samples treated with vehicle or emavusertib & PD-1 ICB. (A) IHC of resected B16F10 tumors reveals reduced myeloid (TAM) infiltration (F4/80, white) and PD-L1 (

  121. Slide 121: CA-4948 plus aPD1 improves survival in murine MBM models

    Combination CA-4948 plus aPD1 therapy improves survival in murine models of MBM von Roemeling CA, et al. Cancer Res. 2023; 83(8_suppl): LB203-LB203. 121

  122. Slide 122: CA-4948 plus Pembrolizumab in MBM patients following SRS

    Combination CA-4948 plus Pembrolizumab in MBM patients following SRS Start of Study after On treatment Screening and completion of SRS and systemic metastasis Enrollment baseline biopsy of systemic biopsy metastasis if present Phase I: CA-4948 Phase Il: Diagnosis of Treatment with 200mg BID + 1° End

  123. Slide 123: Questions?

    IRAK4 | Symposium Questions? fon CUS’

  124. Slide 124: IRAK4 inhibition to overcome myeloid cell-mediated resistance in bladder cancer

    IRAK4 inhibition to overcome myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer Matthew D. Galsky, M.D. Professor of Medicine (Hematology and Medical Oncology) Director of Genitourinary Medical Oncology Co-Director of the Center of Excellence for Bladder Cancer Associat

  125. Slide 125: Drug development for metastatic bladder cancer was stagnant for years

    Drug development for metastatic bladder cancer was stagnant for years FDA Approvals for Bladder Cancer Drugs 6 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Galsky MD, et al. Clin Cancer

  126. Slide 126: IRAK4 | Symposium

    IRAK4 | Symposium ay CURIS

  127. Slide 127: What is a hot tumor?

    Nice conceptual framework….but really what is a “hot” tumor?? 127

  128. Slide 128: What is a hot tumor?

    Nice conceptual framework…. but really what is a “hot” tumor? Hanahan, et al. Cell. 2011; 144(5):646-74. 128

  129. Slide 129: Surrogates of tumor promoting inflammation predict survival

    Relative importance of top 10 variables for predicting survival in patients with metastatic UC treated with atezolizumab using machine-learning models • Surrogates of tumor promoting inflammation are among the most powerful and reproducible poor prognostic indicators in metastatic urothelial cancer

  130. Slide 130: Gene signatures associated with response/resistance to PD-1/PD-L1 blockade

    We previously identified, and validated, two gene signatures associated with response/resistance to PD-1/PD-L1 blockade in bladder cancer Test Cohort Validation Cohort • Higher ratio of adaptive immune response:tumor promoting inflammation signature = better outcomes • Lower ratio of adaptive immune

  131. Slide 131: Cellular origins of immune and inflammation gene signatures using scRNAseq

    Defining the cellular origins of adaptive immune and pro-tumorigenic inflammation gene signatures using scRNAseq 81,269 cells Tumor promoting inflammation signature Adaptive immune signature 27 tumors +3 normal adjacent tissue CD4 T CD4 Treg DC CD8 T Myeloid_2 Mast Myeloid_1 Plasma ILC3 B NK pDC Dat

  132. Slide 132: Monocytes and macrophages underlie tumor promoting inflammation signature

    Monocytes and macrophages (MΦs) underlie the tumor promoting inflammation signature in BC tumors FCGR3A CD14 CD14 Mono 1 FCN1 CD14 Mono 2 LYZ Macro_C1QC_high CD68 Macro_SPP1 CD14 Mono 1_IL1B CD163 Macro_C1QC_intermidiate MRC1 CD16 Mono C1QC Macro_Proliferative SPP1 IL1B NLRP3 CLEC5A TREM1 IL6 Data g

  133. Slide 133: Monocytes and macrophages underlie tumor promoting inflammation signature

    Monocytes and macrophages (MΦs) underlie the tumor promoting inflammation signature in BC tumors FCGR3A CD14 CD14 Mono 1 FCN1 CD14 Mono 2 LYZ Macro_C1QC_high CD68 Macro_SPP1 CD14 Mono 1_IL1B CD163 Macro_C1QC_intermidiate MRC1 CD16 Mono C1QC Macro_Proliferative SPP1 IL1B NLRP3 CLEC5A TREM1 IL6 Highes

  134. Slide 134: Transcriptional dichotomy of MΦs across tumor types

    There is a transcriptional dichotomy of MΦs seen across multiple tumor types GSEA from Ingenuity Pathway Analysis C1QChigh MΦs SPP1high MΦs C1QC macrophages Antigen presentation pathway Th2 pathway C1QChigh MΦs Th1 and Th2 activation pathway Th1 pathway Complement system 0 5 10 15 20 SPP1 MΦs -log(p

  135. Slide 135: Transcriptional dichotomy of MΦs across tumor types

    There is a transcriptional dichotomy of MΦs seen across multiple tumor types C1QChigh MΦs SPP1high MΦs GSEA from Ingenuity Pathway Analysis C1QC macrophages SPP1 MΦs C1QC high MΦs SPP1high MΦs Antigen presentation pathway IL-6 signaling Th2 pathway TREM1 signaling Th1 and Th2 activation pathway HIF1

  136. Slide 136: SPP1high MoMacs associated with poor outcomes

    SPP1high MoMacs associated with poor outcomes across multiple solid tumors Zhang L, et al. Cell. 2020 Bill R, et al. Science. 2023 1. Zhang L, et al. Cell. 2020;181(2):442-459.e29. 2. Bill R, et al. Science. 2023;381(6657):515-524. 136

  137. Slide 137: IL-1 top inferred ligand for SPP1high MΦs

    IL-1 top inferred ligand leading to this transcriptional state of SPP1high MΦs Wang L, et al. Clinical Cancer Res. 2021; 27(15):4287-4300. 137

  138. Slide 138: Modeling SPP1high MΦs for further characterization

    Modeling SPP1high MΦs for further characterization Data generated by Michelle Tran. ELISA, enzyme-linked immunosorbent assay; GM-CSF, granulocyte-macrophage colony-stimulating factor; RT-qPCR, real-time quantitative polymerase chain reaction.. 138

  139. Slide 139: IL-1β stimulation recapitulates SPP1high MΦ program

    IL-1β stimulation recapitulates SPP1high MΦ transcriptional program RT-PCR Bulk RNA-seq Legendplex CBA on supernatant TREM1 CLEC5A SPP1 IL-6IL-6 40 25 6 Unstimulated MΦs IL-1β stimulated MΦs 5000 IL-6 concentration (pg/mL) relative fold change relative fold change 20 relative fold change 4000 30 4 1

  140. Slide 140: Model of emergence of MΦ phenotypes in urothelial cancer TME

    Model of emergence of MΦ phenotypes in urothelial cancer TME with dichotomous phenotypes and function 140

  141. Slide 141: CA-4948 modulates the SPP1high MΦ transcriptional program

    Koziczak-Holbro, M. et al (2008) MΦ transcriptional program relative fold change 0 1 2 3 4 5 IL IL -1 β -1 β U + + S C D A4 94 M SO 8 (1 0 IL1B µM ) relative fold change 0 1 2 3 4 5 IL IL -1 β -1 β U + + S relative fold change C D A4 M 0 2 4 6 94 SO IL 8 -1 IL (1 β -1 U 0 + β S µM CLEC5A C + ) D A4

  142. Slide 142: Phase 1 trial of CA-4948 with pembrolizumab in urothelial cancer

    Phase 1 Trial of CA-4948 in combination with pembrolizumab to overcome resistance to PD-1/PD-L1 blockade in metastatic urothelial cancer NCI ETCTN 142

  143. Slide 143: Acknowledgements

    Cancer Genetics and Bladder Cancer Immunotherapy Genomic Sciences Program Program Jun Zhu PhD John Sfakianos MD Robert Sebra PhD Peter Wiklund MD PhD Nina Bhardwaj MD PhD Kristin Beaumont PhD Reza Mehrazin MD Sacha Gnjatic PhD Che-kai Tsao MD Benjamin Hopkins PhD Amir Horowitz PhD Tomi Jun MD Li Wan

  144. Slide 144: Questions?

    IRAK4 | Symposium Questions? fon CUS’

  145. Slide 145: We will now take a short break

    We will now take a short break Please return at 11:35am ET 145

  146. Slide 146: IRAK4 Inhibition in Lymphoma and Myeloma

    IRAK4 Inhibition in Lymphoma and Myeloma Claudio Cerchione, M.D., Ph.D. Hematologist, Istituto Scientifico Romagnolo per Io Studio e la Cura dei Tumori (IRST) IRCCS 146

  147. Slide 147: Background

    Background BCR and TLR Pathways independently drive NF-κB overactivity In preclinical testing, blocking both IRAK4 and BTK (IMBRUVICA Package Insert. Rev 08/2018) drove tumor reduction better than blocking either one alone (Booher et al. Waldenström Roadmap Symposium 2019) • IRAK4 is essential for T

  148. Slide 148: TakeAim-Lymphoma: Study Design

    TakeAim-Lymphoma (NCT03328078): Study Design 1. Part A1: dose escalation of emavusertib as monotherapy 2. Part A2: dose escalation of emavusertib in combination with ibrutinib - Endpoints of Part A1 and A2 include safety, tolerability, and RP2D - Treatment: Oral, once-daily (QD), or twice-daily (BID

  149. Slide 149: Emavusertib Monotherapy in B Cell Cancers

    Emavusertib Monotherapy in B Cell Cancers Percent Change in Tumor Burden from Baseline (6 patients treated for ~ 1 year or longer) • 6 patients were treated with emavusertib for ≥1 year 20 10 - 3 patients ongoing with treatment with duration ranging 19- 41 months Percent Change from Baseline in Tumo

  150. Slide 150: Emavusertib + Ibrutinib in R/R Hematological Malignancies

    Emavusertib + Ibrutinib in R/R Hematological Malignancies Evaluable Patients Best response Change in tumor burden over time Patient diagnosis CNS MZL MCL CLL MCL WM MZL-N MZL-N CNS * Indicates patient is ongoing with treatment • 4 patients that received prior BTK treatment show promising anti-cancer

  151. Slide 151: Preliminary Efficacy Data From Combination Therapy

    Preliminary Efficacy Data From Patients with Combination Therapy Key Takeaways MCL • In prior clinical studies oral emavusertib MCL CNS monotherapy appears to be well Individual Patient Diagnosis CLL tolerated with an acceptable long term MZL DLBCL safety profile Indicates time of response DLBCL MZL

  152. Slide 152: Emavusertib in Lymphoma

    Emavusertib in Lymphoma • Patients are currently treated with BTKi because it downregulates NF-κB • Two pathways drive NF-κB: - BCR Pathway: addressed by blocking BTK - TLR Pathway: addressed by blocking IRAK4 • Initial clinical data suggest blocking both pathways may overcome resistance to ibrutini

  153. Slide 153: Preliminary Clinical Results in PCNSL

    Preliminary Clinical Results in PCNSL • Preliminary efficacy data: 1 CR and 1 SD • Case 1 was originally intolerant to high-dose methotrexate-based chemoimmunotherapy & achieved PR after switching to ibrutinib. Patient then achieved CR with combination ibrutinib + emavusertib • Case 2 achieved and m

  154. Slide 154: CA-4948-101: Dose-Expansion Study in R/R PCNSL

    CA-4948-101: Dose-Escalation and -Expansion Study of Emavusertib in Patients With R/R PCNSL Part B: Dose Expansion Patient Population Study Treatment Endpoints ~20 patients with R/R PCNSL Emavusertib Primary: • Previously received ≤3 lines of 100-200 mg BID prior anti-PCNSL therapy, • Safety (AEs) i

  155. Slide 155: Multiple Myeloma: Natural History

    Multiple Myeloma: Natural History 155

  156. Slide 156: Multiple myeloma treatment evolution

    Proteasome Immunomodulatory —_ ead Inhibitors Drugs 1 generation Velcade® (Bortezomib) 24 generation Revlimid® (lenalidomide) io CURIS > 2010 Doublet Therapy IRAK4 | Symposium HDAC inhibitors Antibody drug conjugates Bispecific antibodies Chimeric antigen receptor T cells Blenrep® (Bleantamab Mafodo

  157. Slide 157: Plasma cells from myeloma patients express PD-L1

    Sue ag SERVIZIO SANITARIO REGIONALE SCENTRCO. EVILIA-ROMAGNA, ROMAGNO® 10° Shaiitintmntrsiescnain FeigspsrAar (LCF SONO™E, & é ‘none eeener ont ‘Toevrieurnacacay IRAK4 | Symposium NEOPLASIA | JULY 1, 2007 Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after

  158. Slide 158: Gene-expression-profiling Prognostic Index in Myeloma (GIMPI)

    Gene-expression-profiling plus Integrated Multidisciplinary approach to detect new-generation risk-adapted Prognostic Index in Smoldering Myeloma and Multiple Myeloma (GIMPI) (Myeloma Team IRST: Claudio Cerchione, Sonia Ronconi, Delia Cangini, Michela Ceccolini) A prognostic score combining differen

  159. Slide 159: Gene-expression-profiling Prognostic Index in Myeloma (GIMPI)

    Gene-expression-profiling plus Integrated Multidisciplinary approach to detect new-generation risk-adapted Prognostic Index in Smoldering Myeloma and Multiple Myeloma (GIMPI) (Myeloma Team IRST: Claudio Cerchione, Sonia Ronconi, Delia Cangini, Michela Ceccolini) A prognostic score combining differen

  160. Slide 160: IRAK4 in Hematologic Malignancies dinner symposium

    IRAK4 in Hematologic Malignancies dinner symposium Evening of Wednesday Oct 4th Claudio Cerchione, Giovanni Martinelli, Guillermo Garcia Manero, Naval Daver, and Elias Jabbour IRAK4 Inhibition in Myeloma and Lymphoma | 160 Dr. Claudio Cerchione, MD, PhD Presentazione delle attività svolte durante il

  161. Slide 161: IRAK1 and IRAK4 as emerging targets in hematologic malignancies

    IRAK4 | Symposium [oPeN] IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies Joshua Bennett®® and Daniel T. Starczynowski*? ORIGINAL ARTICLE A phase 2 trial reported that the IL-1 receptor antag- Induction of a Chronic Disease State in Patients With Smoldering onist Anakinra

  162. Slide 162: Acknowledgements

    Acknowledgements IRST IRCCS – Meldola (FC) - Scientific Director IRST IRCCS – Hematology Division –Meldola (FC) • Prof. Giovanni Martinelli • Dott.ssa Benedetta Maria Giannini • Dott. Alessandro Lucchesi IRST IRCCS – Meldola (FC) – Head of Hematology • Dott. Francesco Malaspina • Dott. Gerardo Musur

  163. Slide 163: Questions?

    IRAK4 | Symposium Questions? fon CUS’

  164. Slide 164: PCNSL Overview, Current Treatment Strategies, and IRAK4 Inhibition

    PCNSL Overview, Current Treatment Strategies, and IRAK4 Inhibition Christian Grommes, M.D. Associate Professor of Neurology, Weill Cornell Medical College; Assistant Professor of Neuroscience, Brain and Mind Research Institute, Weill Cornell Medical College; Neuro-oncologist, Memorial Sloan-Ketterin

  165. Slide 165: Primary Central Nervous System Lymphoma

    Primary Central Nervous System Lymphoma • Aggressive Non-Hodgkin Lymphoma • >95% are Diffuse Large B-cell Lymphoma (CD20+; >80% ABC subtype) • Confined to brain, spinal cord, CSF or eyes • Characteristic angiocentric growth pattern on histology • In immunocompetent and immunosuppressed patients • 4%

  166. Slide 166: Epidemiology

    Epidemiology A rising Incidence rates differed Approximately incidence between young and elderly 1,500 since the PCNSLs in the US Age 20-29: Age 70-79: 1970s 0.08 4.32 Mendes JS, et al., Neuro Oncol. 2018;20(5):687-694. 166

  167. Slide 167: Clinical Features of PCNSL

    Median age: 60-65 28% hemiparesis Gender: men/women - 1:1 Clinical Clinical 13% seizures Features of Features of In patients with ocular Clinical symptoms develop over weeks PCNSL PCNSL involvement: blurred vision, “floaters” 51% behavioral/personality/ cognitive dysfunction B-symptoms are rare Grom

  168. Slide 168: Disease sites and staging assessments

    Disease sites Staging Assessments • Intra-cranial lesions • Systemic staging • Neurologic staging: • 10-20% ocular involvement MRI brain/spine, CSF, - HIV status • 7-42% positive CSF cytology Ocular exam - PET/CT chest/abdomen/pelvis • Isolated leptomeningeal involvement <5% - Bone marrow biopsy • S

  169. Slide 169: Pathologic Features of PCNSL

    Pathologic Features of PCNSL Angiocentric Growth Pattern • Majority are DLBCL (CD20+) • 10% are T-cell, indolent B-cell, or Burkitt-lymphoma • PCNSL have a high proliferation index (Ki67 usually >50%) • Majority (>80%) are of the non-germinal center subtype DLBCL, diffuse large B cell lymphoma; PCNS

  170. Slide 170: Central Role of BCR Signaling in PCNSL

    Central Role of B-cell Receptor (BCR) Signaling in PCNSL Mutation Frequencies in PCNSL PCNSL, primary central nervous system lymphoma. 1. Grommes C, et al. Cancer Discov. 2017;7(9):1018-1029. 2. Braggio E, et al. Clin Cancer Res. 2015;21(17):3986-3994. 3. Bruno A, et al. Oncotarget. 2014;5(13):5065-

  171. Slide 171: Treatment of PCNSL

    Treatment of PCNSL • Without therapy: 1.5-3 months survival • Worse outcome compared to systemic DLBCL were >50% are long-term survivors • Standard systemic regimens (CHOP) are ineffective due to poor Blood Brain Barrier penetration • No uniform consensus on optimal management • Treatment sensitive

  172. Slide 172: General PCNSL Treatment Scheme

    General PCNSL Treatment Scheme Additional Recurrence First Recurrence Initial Diagnosis Diagnosis: Diagnosis: Diagnosis: • MR Imaging • MR Imaging • MR Imaging • Biopsy • Biopsy • Biopsy • CSF • CSF • CSF • Systemic staging • Systemic staging • Systemic staging First Line Therapy Salvage Therapy Sal

  173. Slide 173: Controversies

    Controversies What is the ideal upfront regimen? • Induction regimen - Rituximab – Methotrexate – Vincristine – Procarbazine (R-MVP) - Rituximab – Methotrexate – Temozolomide (R-MT) - Rituximab – Methotrexate – Cytarabine – Thiotepa (MATRix) - Rituximab – Methotrexate – BCNU – Etoposide – Prednisone

  174. Slide 174: Prognostic Models and Outcomes

    Prognostic Models Outcomes • MSKCC prognostic model for PCNSL • Nationwide median overall survival doubled in the last 40yrs - 2 significant variables: Age and KPS - 12.5 months in the 1970s versus 26 months in the 2010s - RPA Class I-III • No improvement in pts >70 • IELSG prognostic model - 6 mont

  175. Slide 175: Challenges of First-Line Treatment

    Rate of Treatment Treatment-induced Refractory Patients Leukoencephalopathy • 10-15% have primary • Particularly with radiation refractory disease Challenges High Relapse Rate of First-Line Response Vary Based • 50% relapse • Median time to relapse Treatment on Age • MSK prognostic score is 10-18 mo

  176. Slide 176: Integration of Novel Agents in First-Line Therapy

    Integration of Novel Agents in First-Line Therapy French Study Alliance: MSK: Wash U: Ono: Elderly only: (iLOC): R-M + R-MVP + R-MVP + R-MVP followed R-MVP or R-MT MSK lenalidomide + ibrutinib vs. R- ibrutinib by nivolumab with tirabrutinib Copanlisib and nivolumab MVP + maintenance Ibrutinib as fir

  177. Slide 177: Treatment at Recurrence

    Treatment at Recurrence Regimen used: Median time to progression 10-18 months • High-dose Methotrexate re-challenge • Palliative radiation Elderly population: 75% Progress within 2 years • Radiation and Chemotherapy is challenging Conventional non-MTX chemotherapy Prognosis is poor with limited resp

  178. Slide 178: Single Agent Responses with Targeted Therapies

    Single Agent Responses with Targeted Therapies 1. Tun et al., Blood. 2018. 2. Soussain, et al. Eur J Cancer. 2019. 3. Ghesquieres, et al., Ann Oncol. 2019. 4. Grommes et al., ASCO 2017. 178

  179. Slide 179: Treatment Options per NCCN guidelines

    Treatment Options per NCCN guidelines • MTX +/- rituximab • MTX re-challenge • Temozolomide • Consider ASCT if not given as first-line • Rituximab +/- temozolomide • Palliative WBRT • Topotecan • Clinical trial enrollment • High-dose cytarabine • Pemetrexed • Dexamethasone, high-dose cytarabine, cis

  180. Slide 180: Combination Therapies Might Increase Efficacy

    Combination Therapies Might Increase Efficacy Emavusertib + Chemotherapy + Radiation + CAR-T cells + Immune checkpoint inhibitors 180

  181. Slide 181: IRAK4 inhibition in PCNSL – ongoing trial

    IRAK4 inhibition in PCNSL – ongoing trial - all Ibrutinib resistant - 181

  182. Slide 182: Conclusions

    HD-MTX based polychemotherapy Identify ideal treatment regimen for regimen is backbone elderly patients MTX-based chemotherapy has Clinical Targeting the BCR signaling axis has significantly increased clinical outcomes Features of Conclusions promising clinical activity in recurrent/refractory PCNSL

  183. Slide 183: Questions?

    IRAK4 | Symposium Questions? fon CUS’

  184. Slide 184: Biomarkers for IRAK4 and inflammation in myeloid malignancies

    Biomarkers for IRAK4 and inflammation in myeloid malignancies Daniel Starczynowski, Ph.D. Institute Associate Director for Basic Science Research, University of Cincinnati Cancer Center; Co-Chief Scientific Officer, Innovations Ventures; Katherine Stewart Waters Endowed Chair of Hematologic Malignan

  185. Slide 185: Inflammation and innate immune signaling underlies myeloid malignancies

    Overview: Inflammation and innate immune signaling underlies the pathogenesis of myeloid malignancies Cell-intrinsic innate immune dysregulation: • Molecular and genetic alterations lead to dysregulation of innate immune pathways in CHIP and MDS/AML HSPCs. • Co-option of innate immune pathways contr

  186. Slide 186: Option 1: Measurement of inflammatory markers

    Option 1: Measurement of inflammatory markers IL1b (IL1R) pro-inflammatory cytokine, expansion of clones, NF-kB activation IL6 (IL6R) pro-inflammatory cytokine, expansion of clones, JAK/STAT and NF-kB activation IL8 (CXCR1/2) pro-inflammatory cytokine, expansion of clones, NF-kB, MAPK, and PI3K acti

  187. Slide 187: Option 2: Measurement of intracellular signaling

    Option 2: Measurement of intracellular signaling related to inflammation AML Pancreatic Cancer • Total vs nuclear IRAK4 • Phospho-IRAK4 or -IRAK1 • NF-kB - Phospho- p50, p65/RelA, IKK, Isolated cells: immunoblotting, IHC, FACS 1. Ugolkov A, et al. Poster presented at: European Hematology Association

  188. Slide 188: Option 3: Predictive gene expression signatures

    Option 3: Predictive gene expression signatures IRAK4 isoform expression IRAK1/4 gene signature iScore Isolated cells: RNA-seq 1. Smith MA, et al. Nat Cell Biol. 2019;21(5):640:650. 2. Bennett JR, et al. Blood. 2023;142(11):989-1007. 3. Lasry A, et al. Nat Cancer. 2023;4(1):27-42. 188

  189. Slide 189: Overview of assessing inflammation in MDS/AML

    Overview of assessing inflammation in MDS/AML • MDS/AML exhibit extensive inflammation and altered immune-related pathways. - Inflammation-related biomarkers for MDS/AML are lacking • Several biomarker strategies are available: - Measurement of inflammatory cytokines - Measurement of intracellular s

  190. Slide 190: Questions?

    IRAK4 | Symposium Questions? fon CUS’

  191. Slide 191: Panel Discussion of IRAK4 and its Inhibition

    Panel Discussion of IRAK4 and its Inhibition Richard Stone, M.D. Chief of Staff, Dana-Farber Cancer Institute; Director of Translational Research, Adult Acute Leukemia Program, Dana-Farber Cancer Institute; Professor of Medicine, Harvard Medical School Guillermo Garcia-Manero, M.D. Symposium Co-Chai

  192. Slide 192: Thank you!

    IRAK4 | Symposium Thank you! fon CUS’

Curis — Technical Presentation (September 2023) on 6ix